Pfizer (PFE) : First Mercantile Trust Co reduced its stake in Pfizer by 10.16% during the most recent quarter end. The investment management company now holds a total of 23,000 shares of Pfizer which is valued at $771,880 after selling 2,600 shares in Pfizer , the firm said in a disclosure report filed with the SEC on Oct 7, 2016.Pfizer makes up approximately 0.10% of First Mercantile Trust Co’s portfolio.
Other Hedge Funds, Including , Central Bank Trust Co reduced its stake in PFE by selling 956 shares or 1.72% in the most recent quarter. The Hedge Fund company now holds 54,753 shares of PFE which is valued at $1,837,511. Pfizer makes up approx 0.52% of Central Bank Trust Co’s portfolio.Hefty Wealth Partners reduced its stake in PFE by selling 49,033 shares or 99.62% in the most recent quarter. The Hedge Fund company now holds 189 shares of PFE which is valued at $6,407.Burns J W Co Incny reduced its stake in PFE by selling 731 shares or 0.75% in the most recent quarter. The Hedge Fund company now holds 96,183 shares of PFE which is valued at $3,260,604. Pfizer makes up approx 1.01% of Burns J W Co Incny’s portfolio.Boltwood Capital Management reduced its stake in PFE by selling 2,853 shares or 0.91% in the most recent quarter. The Hedge Fund company now holds 312,390 shares of PFE which is valued at $10,590,021. Pfizer makes up approx 8.52% of Boltwood Capital Management’s portfolio.Eqis Capital Management boosted its stake in PFE in the latest quarter, The investment management firm added 2,545 additional shares and now holds a total of 38,771 shares of Pfizer which is valued at $1,314,337. Pfizer makes up approx 0.08% of Eqis Capital Management’s portfolio.
Pfizer closed down -0.09 points or -0.27% at $33.56 with 1,48,19,706 shares getting traded on Friday. Post opening the session at $33.7, the shares hit an intraday low of $33.42 and an intraday high of $34 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Pfizer reported $0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $13147.00 million for the quarter, compared to analysts expectations of $13013.24 million. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 EPS.
Investors should note that on Sep 22, 2016, Pfizer announced a cash dividend of $0.3000. The company’s management has announced Nov 9, 2016 as the ex-dividend date and fixed the record date on Nov 11, 2016. The payable date has been fixed on Dec 1, 2016.
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.